Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $580.45, for a total value of $5,514,275.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at $23,515,770.85. This represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $571.73 on Friday. The stock’s 50 day moving average price is $516.68 and its 200 day moving average price is $484.30. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $607.89. The company has a market capitalization of $25.06 billion, a P/E ratio of 20.49, a P/E/G ratio of 1.65 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the prior year, the company posted $6.19 earnings per share. The firm’s revenue was up 7.4% on a year-over-year basis. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently modified their holdings of the business. Torren Management LLC acquired a new position in United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC bought a new stake in United Therapeutics in the 4th quarter valued at $31,000. Wilmington Savings Fund Society FSB boosted its holdings in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. bought a new stake in United Therapeutics in the 4th quarter valued at $48,000. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on UTHR. Royal Bank Of Canada upped their target price on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Bank of America upped their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. HC Wainwright upped their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Finally, Morgan Stanley upped their target price on United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a research report on Friday. Ten equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $601.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.